USPH

U.S. Physical Therapy, Inc. (USPH) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. U.S. Physical Therapy, Inc. operates two primary segments: Physical Therapy Operations (outpatient clinics) and Industrial Injury Prevention (IIP) services. As of the reporting date, the Company operated 661 clinics in 42 states and managed an additional 39 third-party clinics. The Company continues an active acquisition strategy, adding 33 clinics in the first nine months of 2024 while closing 43 underperforming locations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 12.0% in Q3 and 9.1% YTD, driven by a 6.0% increase in patient visits and a 3.2% increase in net rate per visit, despite a 1.8% Medicare rate reduction in 2024.
• Clinic Closures: The Company incurred $3.4 million in closure costs in Q3 (32 clinics) and $4.1 million YTD (43 clinics). Excluding these costs, adjusted gross margins improved to 19.4% in Q3 and 19.5% YTD.
• Segment Performance:
  • Physical Therapy: Revenue grew 9.3% in Q3. Gross margin was 16.5% (18.9% excluding closure costs).
  • IIP Services: Revenue grew 29.9% in Q3 to $25.3 million, with a gross margin of 22.2%.
• Non-GAAP Adjustments: Adjusted EBITDA increased to $21.1 million in Q3 (from $18.6 million prior year). Operating Results per share were $0.69 in Q3 (from $0.62 prior year).
• Acquisitions: Significant acquisitions in 2024 included a 70% interest in an 8-clinic practice (Aug), a 100% IIP business (Apr), and a 50% interest in a 9-clinic practice (Mar).

Guidance, Outlook, and Risks

• Subsequent Event: On October 31, 2024, the Company acquired a 50% interest in MSO Metro, LLC for approximately $76.5 million (funded by cash and stock), with a potential $20.0 million earn-out.
• Dividends: The Board declared a quarterly dividend of $0.44 per share, payable December 6, 2024.
• Liquidity: The Company maintains a $325 million credit facility ($175M revolving, $150M term). As of Sept 30, 2024, $140.6 million was outstanding on the term loan with $175.0 million available on the revolver. Management believes cash and credit are sufficient through September 2025.
• Risks:
  • Regulatory: Potential impact of FTC rules on non-compete agreements with therapists, which could lead to staff loss.
  • Reimbursement: Ongoing pressure from Medicare rate reductions and third-party payer contract negotiations.
  • Integration: Risks associated with integrating recent acquisitions, particularly the large Metro transaction.

Investor Verification Checklist

• Closure Cost Impact: Verify the sustainability of margins by reviewing the "Adjusted" (non-GAAP) metrics which exclude the $4.1M in YTD clinic closure costs.
• Acquisition Integration: Monitor the financial impact and integration progress of the $76.5M MSO Metro acquisition completed in October 2024.
• Debt Covenants: Confirm continued compliance with the Credit Agreement covenants (Leverage Ratio and Fixed Charge Coverage) following the Metro acquisition.
• Non-Controlling Interest (NCI): Review the revaluation of redeemable NCI ($3.2M charge YTD), which impacts EPS but not GAAP Net Income.
• Medicare Rates: Assess the long-term impact of the 1.8% Medicare rate reduction effective March 2024 and the proposed 2.8% reduction for 2025.